FRANKFURT—Europe’s drugmakers have warned they may stop making some cheap generic medicines because of surging electricity costs and are calling for an overhaul of the way they are priced, the latest industry to seek help as the energy crisis deepens.
The generic drug industry lobby group Medicines for Europe, which represents companies including Teva, Novartis’s Sandoz unit, and Fresenius SE’s Kabi business, on Tuesday sent an open letter to European Union member states’ energy and health ministers.
